Security National Bank Trims Stake in Zoetis Inc. $ZTS

Security National Bank lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 93.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,358 shares of the company’s stock after selling 50,512 shares during the quarter. Security National Bank’s holdings in Zoetis were worth $423,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis during the 4th quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis during the 3rd quarter valued at about $31,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis during the 4th quarter valued at about $30,000. Holos Integrated Wealth LLC bought a new stake in shares of Zoetis during the 4th quarter valued at about $32,000. Finally, Board of the Pension Protection Fund bought a new stake in shares of Zoetis during the 4th quarter valued at about $38,000. Institutional investors own 92.80% of the company’s stock.

Insider Activity

In related news, Director Paul Bisaro bought 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 11,650 shares of company stock valued at $886,384. Insiders own 0.22% of the company’s stock.

Zoetis Price Performance

ZTS opened at $74.11 on Friday. The stock has a 50-day moving average price of $112.28 and a 200-day moving average price of $120.94. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $172.23. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a market capitalization of $31.07 billion, a P/E ratio of 12.29, a PEG ratio of 1.21 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the previous year, the company posted $1.48 earnings per share. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts predict that Zoetis Inc. will post 6.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Citigroup assumed coverage on Zoetis in a research report on Wednesday, April 15th. They set a “buy” rating and a $145.00 price target for the company. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Stifel Nicolaus set a $105.00 price objective on Zoetis in a report on Friday, May 8th. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $137.50.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.